Monthly report from the EU Pharmacovigilance Risk Assessment Committee (PRAC) - October 2014

14 October 2014

The EU Pharmacovigilance Risk Assessment Committee (PRAC) convened on 6-9 October 2014. Topics discussed at the meeting:

  • PRAC recommends strengthening the restrictions on the use of valproate in women and girls
  • PRAC review does not confirm increase in heart problems with testosterone medicines
  • PRAC recommends further measures to minimise risk of blood vessel blockage with Iclusig
  • Five days left to respond to the consultation on public hearings

Read PRAC's monthly report from the meeting 6-9 October 2014

Did you get answers to your questions?

Please tell us how we can improve our website? Please note that we do not answer questions asked via this feature.